Year |
Citation |
Score |
2023 |
Fasching PA, Szeto C, Denkert C, Benz S, Weber K, Spilman P, Budczies J, Schneeweiss A, Stickeler E, Schmatloch S, Jackisch C, Karn T, Sinn HP, Warm M, van Mackelenbergh M, et al. Inferred immune-cell activity is an independent predictor of HER2 negative breast cancer prognosis and response to paclitaxel-based therapy in the GeparSepto trial. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 37014668 DOI: 10.1158/1078-0432.CCR-22-2213 |
0.659 |
|
2022 |
Burton KA, Mahen E, Konnick EQ, Blau S, Dorschner MO, Ramirez AB, Schmechel SC, Song C, Parulkar R, Parker S, Senecal FM, Pritchard CC, Mecham BH, Szeto C, Spilman P, et al. Safety, Feasibility, and Merits of Longitudinal Molecular Testing of Multiple Metastatic Sites to Inform mTNBC Patient Treatment in the Intensive Trial of Omics in Cancer. Jco Precision Oncology. 6: e2100280. PMID 35294224 DOI: 10.1200/PO.21.00280 |
0.618 |
|
2020 |
Newton Y, Sedgewick AJ, Cisneros L, Golovato J, Johnson M, Szeto CW, Rabizadeh S, Sanborn JZ, Benz SC, Vaske C. Large scale, robust, and accurate whole transcriptome profiling from clinical formalin-fixed paraffin-embedded samples. Scientific Reports. 10: 17597. PMID 33077815 DOI: 10.1038/s41598-020-74483-1 |
0.722 |
|
2020 |
Adashek JJ, Kato S, Parulkar R, Szeto CW, Sanborn JZ, Vaske CJ, Benz SC, Reddy SK, Kurzrock R. Transcriptomic silencing as a potential mechanism of treatment resistance. Jci Insight. 5. PMID 32493840 DOI: 10.1172/Jci.Insight.134824 |
0.76 |
|
2020 |
Jaber MI, Song B, Taylor C, Vaske CJ, Benz SC, Rabizadeh S, Soon-Shiong P, Szeto CW. A deep learning image-based intrinsic molecular subtype classifier of breast tumors reveals tumor heterogeneity that may affect survival. Breast Cancer Research : Bcr. 22: 12. PMID 31992350 DOI: 10.1186/S13058-020-1248-3 |
0.634 |
|
2020 |
Reddy SK, Seery TE, Szeto C. Results of a fifty-gene breast cancer RNA subtype classifier applied to 167 colorectal cancer (CRC) patients. Journal of Clinical Oncology. 38: 20-20. DOI: 10.1200/Jco.2020.38.4_Suppl.20 |
0.44 |
|
2020 |
Szeto C, Gounder MM, Parulkar R, Nguyen A, Rabizadeh S, Reddy SK. High correlation between TMB, expressed TMB, and neoantigen load using tumor: Normal whole exome DNA and matched whole transcriptome RNA sequencing. Journal of Clinical Oncology. 38. DOI: 10.1200/Jco.2020.38.15_Suppl.E15238 |
0.417 |
|
2020 |
Benz SC, Beziaeva L, Jaber M, Rabizadeh S, Szeto C. Highly accurate automated tissue classification using deep learning on digital pathology images: A novel tool for resolving conflicts in diagnosis. Journal of Clinical Oncology. 38: 3578-3578. DOI: 10.1200/Jco.2020.38.15_Suppl.3578 |
0.643 |
|
2020 |
Adashek JJ, Szeto C, Sanborn JZ, Reddy SK, Toor AA, Danielides S, Smith S, Grossman SR, Clevenger CV, Faber A, Ferreira-Gonzalez A, Boikos SA. Targetable immune checkpoint molecules may be significantly differentially expressed in minority ethnicities. Journal of Clinical Oncology. 38: 3576-3576. DOI: 10.1200/Jco.2020.38.15_Suppl.3576 |
0.465 |
|
2020 |
Szeto C, Veerapaneni S, Parulkar R, Reddy SK, Rabizadeh S, Benz SC. Effect of chemokine signaling signatures on resolving discrepancy between TMB and checkpoint expression. Journal of Clinical Oncology. 38: 3131-3131. DOI: 10.1200/Jco.2020.38.15_Suppl.3131 |
0.683 |
|
2020 |
Fasching PA, Denkert C, Benz S, Weber KE, Szeto C, Budczies J, Schneeweiss A, Stickeler E, Schmatloch S, Jackisch C, Karn T, Sinn HP, Warm M, Mackelenbergh Mv, Rabizadeh S, et al. Abstract PD5-08: Tumor immune-cell activity assessed by RNAseq is an independent predictor of therapy response and prognosis after neoadjuvant chemotherapy in HER2 negative breast cancer patients - An analysis of the GeparSepto trial Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-Pd5-08 |
0.703 |
|
2020 |
Szeto C, Denkert C, Fasching PA, Benz S, Weber KE, Budczies J, Schneeweiss A, Stickeler E, Schmatloch S, Jackisch C, Karn T, Sinn HP, Warm M, Mackelenbergh Mv, Rabizadeh S, et al. Abstract P6-10-04: Landscape of immune-cell signatures in early high-risk breast cancer (BC) reveals clinically-relevant enrichment of immune subpopulations Cancer Research. DOI: 10.1158/1538-7445.Sabcs19-P6-10-04 |
0.661 |
|
2020 |
Williams T, Schneeweiss A, Jackisch C, Shen C, Weber K, Fasching P, Denkert C, Furlanetto J, Heinmoller E, Schmatloch S, Karn T, Szeto C, Mackelenbergh Mv, Nekljudova V, Stickeler E, et al. Abstract P1-10-01: Caveolin gene expression predicts for response and clinical outcomes of patients treated with preoperative paclitaxel-based chemotherapy regimens in early stage breast cancer Cancer Research. DOI: 10.1158/1538-7445.Sabcs19-P1-10-01 |
0.388 |
|
2019 |
Loupakis F, Maddalena G, Depetris I, Murgioni S, Bergamo F, Dei Tos AP, Rugge M, Munari G, Nguyen A, Szeto C, Zagonel V, Lonardi S, Fassan M. Treatment with checkpoint inhibitors in a metastatic colorectal cancer patient with molecular and immunohistochemical heterogeneity in MSI/dMMR status. Journal For Immunotherapy of Cancer. 7: 297. PMID 31703605 DOI: 10.1186/S40425-019-0788-5 |
0.421 |
|
2019 |
Wnuk K, Sudol J, Givechian KB, Soon-Shiong P, Rabizadeh S, Szeto C, Vaske C. Deep Learning Implicitly Handles Tissue Specific Phenomena to Predict Tumor DNA Accessibility and Immune Activity. Iscience. 20: 119-136. PMID 31563852 DOI: 10.1016/J.Isci.2019.09.018 |
0.452 |
|
2019 |
Jochems C, Tritsch SR, Knudson KM, Gameiro SR, Rumfield CS, Pellom ST, Morillon YM, Newman R, Marcus W, Szeto C, Rabizadeh S, Wong HC, Soon-Shiong P, Schlom J. The multi-functionality of N-809, a novel fusion protein encompassing anti-PD-L1 and the IL-15 superagonist fusion complex. Oncoimmunology. 8: e1532764. PMID 30713787 DOI: 10.1080/2162402X.2018.1532764 |
0.311 |
|
2019 |
Schwartz S, Szeto C, Tian Y, Cecchi F, Corallo S, Calegari MA, Di Bartolomeo M, Morano F, Raimondi A, Fucà G, Martinetti A, De Pascalis I, Martini M, Belfiore A, Milione M, et al. Refining the selection of patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of O6-methylguanine-DNA-methyltransferase. European Journal of Cancer (Oxford, England : 1990). 107: 164-174. PMID 30579113 DOI: 10.1016/J.Ejca.2018.11.016 |
0.351 |
|
2019 |
Adashek JJ, Kato S, Parulkar R, Szeto C, Reddy SK, Kurzrock R. RNAseq in addition to next generation sequencing in advanced genitourinary cancers reveals transcriptomic silencing of DNA mutations: Implications for resistance to targeted therapeutics. Journal of Clinical Oncology. 37: 583-583. DOI: 10.1200/Jco.2019.37.7_Suppl.583 |
0.448 |
|
2019 |
Pal SK, Szeto C, Reddy SK, Nussenzveig R, Lam RY, Scholz MC, Agarwal N. Concomitant characterization of androgen receptor (AC) and immune checkpoints (ICs) in cell-free (cf) DNA and RNA from patients with metastatic castration resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 37: 286-286. DOI: 10.1200/Jco.2019.37.7_Suppl.286 |
0.346 |
|
2019 |
Szeto C, Garner C, Kazmierczak K, Vaske CJ, Benz SC, Reddy SK. CMS subtypes characterized by high TMB shows immunosuppressive microenvironment that implies resistance to immunotherapy. Journal of Clinical Oncology. 37: 610-610. DOI: 10.1200/Jco.2019.37.4_Suppl.610 |
0.686 |
|
2019 |
Szeto C, Kazmierczak K, Chambers A, Kim YJ, Nguyen A, Tan IB, Benz SC, Vaske CJ. Comprehensive -omic analysis of 152 CRC patients allows greater subclassification than CMS or sidedness alone. Journal of Clinical Oncology. 37: 601-601. DOI: 10.1200/Jco.2019.37.4_Suppl.601 |
0.695 |
|
2019 |
Szeto C, Veerapaneni S, Kazmierczak K, Benz SC, Reddy SK, Yan D. Comprehensive profiling of immune landscape in gastrointestinal (GI) and head and neck (HN) cancers via computational deconvolution. Journal of Clinical Oncology. 37: 579-579. DOI: 10.1200/Jco.2019.37.4_Suppl.579 |
0.703 |
|
2019 |
Newton Y, Golovato J, Tan IB, Lam JYC, Yu G, Koo S, Chua C, Yeong JPS, Ping C, Skanderup A, Göke J, Johnson M, Rabizadeh S, Sanborn JZ, Benz SC, ... ... Szeto C, et al. Genomic and immune infiltration differences between MSI and MSS GI tumors. Journal of Clinical Oncology. 37: 528-528. DOI: 10.1200/Jco.2019.37.4_Suppl.528 |
0.779 |
|
2019 |
Vaske CJ, Garner C, Seery TE, Szeto C, Reddy SK. Clinical trial screening of CDKN2A genomic alterations in patients with pancreatic cancer and hepatobiliary cancers requires greater precision than somatic sequencing alone. Journal of Clinical Oncology. 37: 287-287. DOI: 10.1200/Jco.2019.37.4_Suppl.287 |
0.504 |
|
2019 |
Edenfield WJ, Merchant K, Martin JC, Drusbosky L, Elliott MH, Reddy SK, Szeto C, Cecchi F, Schammel C, Schammel DP, Grinstead RM, Chung KY. Selected reaction monitoring mass spectrometry (SRM-MS) evaluation of HER2 equivocal breast cancer. Journal of Clinical Oncology. 37. DOI: 10.1200/Jco.2019.37.15_Suppl.E12510 |
0.323 |
|
2019 |
Parulkar R, Nguyen A, Sanborn JZ, Vaske CJ, Benz SC, Reddy SK, Kato S, Kurzrock R, Szeto C. Evidence for selective silencing of MHC-binding neoepitopes to avoid immune surveillance. Journal of Clinical Oncology. 37: 2591-2591. DOI: 10.1200/Jco.2019.37.15_Suppl.2591 |
0.669 |
|
2019 |
Drusbosky L, Szeto C, Reddy SK, Ghotra M, Toor AA, Smith S, Faber A, Boikos SA. Tumor mutation burden and PD-L1 expression in SDH/FH mutated solid tumors. Journal of Clinical Oncology. 37: 1524-1524. DOI: 10.1200/Jco.2019.37.15_Suppl.1524 |
0.354 |
|
2019 |
Obeid E, Reddy S, Goldstein L, Daly M, Benz S, Hall M, Szeto C. Abstract P4-03-03: Germline potentially pathogenic variants in breast cancer intrinsic molecular subtypes are not associated with somatic TMB Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-P4-03-03 |
0.456 |
|
2019 |
Gordon EM, Szeto C, Ravicz JR, Reddy S, Morse M, Chawla S, Hall F. Abstract 2556: Enhanced expression of human cyclin G1 (CCNG1) gene in metastatic cancer, a novel biomarker in development for CCNG1 inhibitor therapy Cancer Research. 79: 2556-2556. DOI: 10.1158/1538-7445.Am2019-2556 |
0.481 |
|
2019 |
Newton Y, Szeto C, Vaske C, Reddy L, Reddy S. Abstract 2533: The genomic and transcriptomic landscape of left versus right sided breast cancer in 410 cases Cancer Research. 79: 2533-2533. DOI: 10.1158/1538-7445.Am2019-2533 |
0.452 |
|
2018 |
Wong GS, Zhou J, Liu JB, Wu Z, Xu X, Li T, Xu D, Schumacher SE, Puschhof J, McFarland J, Zou C, Dulak A, Henderson L, Xu P, O'Day E, ... ... Szeto C, et al. Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition. Nature Medicine. PMID 29808010 DOI: 10.1038/S41591-018-0022-X |
0.41 |
|
2018 |
Tan IB, Nguyen A, Vaske CJ, Szeto C, Newton Y, Becht E, Yeong JPS, Benz SC, Thangaraju S, Lim B, Ho D, Lim KHT, Chua CWL, Mathew R, Tang CL, et al. RNA-Seq analyses of immune cell-type enrichments in 158 Asian colorectal cancers (CRCs). Journal of Clinical Oncology. 36: e15597-e15597. DOI: 10.1200/Jco.2018.36.15_Suppl.E15597 |
0.666 |
|
2018 |
Okamura R, Kato S, Parulkar R, Szeto C, Reddy S, Kurzrock R. Genomic landscape of diverse rare tumors: Next-generation sequencing of paired DNA and RNA analysis. Journal of Clinical Oncology. 36: 12114-12114. DOI: 10.1200/Jco.2018.36.15_Suppl.12114 |
0.41 |
|
2018 |
Pal SK, Vanderwalde AM, Szeto C, Benz SC, Sanborn JZ, Vaske CJ, Reddy SK, Hamid O. Co-expression patterns of immune checkpoint molecules in relation to PD-L1 expression. Journal of Clinical Oncology. 36: 12113-12113. DOI: 10.1200/Jco.2018.36.15_Suppl.12113 |
0.748 |
|
2018 |
Schwartz S, Cecchi F, Tian Y, Yau C, Szeto C, Rübner M, Erber R, Beckmann M, Hartmann A, Benz S, Hembrough T, Fasching P. Abstract P2-10-06: Identifying patients sensitive to anthracycline-containing therapy with quantitative proteomic and genomic profiling Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-P2-10-06 |
0.497 |
|
2018 |
Szeto C, Benz S, Nguyen A, Rübner M, Wallwiener D, Tesch H, Hadji P, Fehm T, Janni W, Overkamp F, Lueftner D, Lux M, Wallwiener M, Beckmann M, Huebner H, et al. Abstract P1-07-20: Developing prognostic indicators of poor outcomes in PRAEGNANT metastatic breast cancer cohort Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-P1-07-20 |
0.466 |
|
2018 |
Parulkar R, Benz S, Vaske C, Radenbaugh A, Szeto C. Abstract 1182: Exploring longitudinal intra-tumor heterogeneity in cancer using whole genome sequencing and RNA rescue Tumor Biology. DOI: 10.1158/1538-7445.Am2018-1182 |
0.483 |
|
2017 |
Wnuk K, Sudol J, Rabizadeh S, Soon-Shiong P, Szeto C, Vaske C. Abstract 393: Predicting DNA accessibility in the pan-cancer tumor genome using RNA-Seq, WGS, and deep learning Cancer Research. 77: 393-393. DOI: 10.1158/1538-7445.Am2017-393 |
0.437 |
|
2012 |
Zhu J, Craft B, Swatloski T, Ellrott K, Goldman M, Wilks C, Ma S, Szeto C, Collisson E, Haussler D. Abstract 5087: UCSC Cancer Genomics Browser 2.0 Cancer Research. 72: 5087-5087. DOI: 10.1158/1538-7445.Am2012-5087 |
0.613 |
|
2011 |
Sanborn JZ, Benz SC, Craft B, Szeto C, Kober KM, Meyer L, Vaske CJ, Goldman M, Smith KE, Kuhn RM, Karolchik D, Kent WJ, Stuart JM, Haussler D, Zhu J. The UCSC Cancer Genomics Browser: update 2011. Nucleic Acids Research. 39: D951-9. PMID 21059681 DOI: 10.1093/Nar/Gkq1113 |
0.783 |
|
2011 |
Zhu J, Sanborn JZ, Benz SC, Craft B, Szeto C, Kober KM, Goldman M, Meyer L, Vaske C, Collisson E, Stuart J, Haussler D. Abstract 4985: The UCSC Cancer Genomics Browser Cancer Research. 71: 4985-4985. DOI: 10.1158/1538-7445.Am2011-4985 |
0.751 |
|
2011 |
Ng S, Vaske C, Benz S, Durbin J, Szeto C, Heiser L, Wang N, Korkola J, Bayani N, Spellman P, Gray JW, Haussler D, Stuart J. Abstract 49: Constructing pathway based predictors of cancer clinical outcome Cancer Research. 71: 49-49. DOI: 10.1158/1538-7445.Am2011-49 |
0.622 |
|
2010 |
Vaske CJ, Benz SC, Sanborn JZ, Earl D, Szeto C, Zhu J, Haussler D, Stuart JM. Inference of patient-specific pathway activities from multi-dimensional cancer genomics data using PARADIGM. Bioinformatics (Oxford, England). 26: i237-45. PMID 20529912 DOI: 10.1093/Bioinformatics/Btq182 |
0.752 |
|
2009 |
Zhu J, Sanborn JZ, Benz S, Szeto C, Hsu F, Kuhn RM, Karolchik D, Archie J, Lenburg ME, Esserman LJ, Kent WJ, Haussler D, Wang T. The UCSC Cancer Genomics Browser. Nature Methods. 6: 239-40. PMID 19333237 DOI: 10.1038/Nmeth0409-239 |
0.771 |
|
2009 |
Zhu J, Sanborn J, Wang T, Hsu F, Benz S, Szeto C, Esserman L, Haussler D. UCSC cancer genomics browser. Cancer Research. 69: 2022. DOI: 10.1158/0008-5472.Sabcs-2022 |
0.751 |
|
Show low-probability matches. |